Finance

Lists
PPLPHARMA:NSE
Piramal Pharma Ltd (Mumbai)
₹211.39
-1.45%
(-3.10) 1D
Sep 4, 12:48:13 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for PPLPHARMA...
Open
₹214.99
High
₹217.00
Low
₹210.66
Mkt. cap
278.92B
Avg. vol.
0.00
Volume
1.28M
52-wk high
₹220.36
52-wk low
₹132.30
EPS
-₹2.37
No. of employees
7K
Open
₹214.99
High
₹217.00
Low
₹210.66
Mkt. cap
278.92B
Avg. vol.
0.00
Volume
1.28M
52-wk high
₹220.36
52-wk low
₹132.30
EPS
-₹2.37
No. of employees
7K
About Piramal Pharma Ltd (Mumbai)
CEOPeter DeYoung
Employees7.12K
Founded2020
Headquarters-
SectorPharmaceutical industry
Websitepiramalpharma.com
Last report
Jul 30, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
-₹0.52 / -₹0.61
+15.03%beat
Revenue / Est. (INR)
22.70B / 21.49B
+5.63%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
20.44B
21.40B
27.52B
22.70B
Cost of goods sold
7.02B
7.86B
13.95B
8.52B
Cost of revenue
7.02B
7.86B
13.95B
8.52B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.11B
6.00B
8.19B
6.76B
Operating expense
13.85B
13.71B
11.09B
14.46B
Total operating expenses
20.88B
21.57B
25.04B
22.98B
Operating income
-441.50M
-170.10M
2.47B
-283.50M
Other non operating income
656.00M
432.40M
-977.90M
894.10M
EBT including unusual items
-461.80M
-938.60M
430.00M
-74.60M
EBT excluding unusual items
-461.80M
-527.50M
1.40B
-74.60M
Income tax expense
530.40M
423.30M
518.30M
619.30M
Effective tax rate
-114.85%
-45.10%
120.53%
-830.16%
Other operating expenses
5.71B
5.58B
723.30M
5.47B
Net income
-992.20M
-1.36B
-88.30M
-693.90M
Net profit margin
-4.85%
-6.36%
-0.32%
-3.06%
Earnings per share
-0.75
-0.72
1.32
-0.52
Interest and investment income
-
-
70.70M
-
Interest expense
-824.20M
-892.40M
-805.40M
-880.80M
Net interest expenses
-824.20M
-892.40M
-734.70M
-880.80M
Depreciation and amortization charges
2.03B
2.13B
2.18B
2.24B
EBITDA
1.45B
1.68B
4.32B
1.57B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps